Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Payables (2016 - 2025)

BioCorRx (BICX) has disclosed Payables for 16 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 9.65% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 9.65% year-over-year, with the annual reading at $7.6 million for FY2025, 9.65% up from the prior year.
  • Payables hit $7.6 million in Q4 2025 for BioCorRx, up from $1.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $13.4 million in Q2 2025 to a low of $1.6 million in Q3 2025.
  • Historically, Payables has averaged $5.3 million across 5 years, with a median of $4.6 million in 2023.
  • Biggest YoY gain for Payables was 143.81% in 2025; the steepest drop was 77.75% in 2025.
  • Year by year, Payables stood at $4.0 million in 2021, then increased by 5.7% to $4.2 million in 2022, then grew by 24.98% to $5.3 million in 2023, then surged by 31.62% to $6.9 million in 2024, then grew by 9.65% to $7.6 million in 2025.
  • Business Quant data shows Payables for BICX at $7.6 million in Q4 2025, $1.6 million in Q3 2025, and $13.4 million in Q2 2025.